Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News BioSig Technologies Inc BSGM

Healthcare Medical Devices

BioSig Technologies, Inc. is a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. The Company’s product, the PURE EP Platform, a non-invasive class II device, provides real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures. Integrating with existing systems in the EP lab, PURE EP is... see more

Add To Watchlist

Recent & Breaking News (NDAQ:BSGM)

BioSig and Mayo Clinic Collaborate on New R&D Program to Develop Transformative AI and Machine Learning Technologies for its PURE EP(TM) System

GlobeNewswire February 2, 2021

Live Investor Conference & Webinar: Small and Microcap Company Showcase on February 4th

Canada NewsWire January 28, 2021

BioSig CEO Kenneth L. Londoner to Present at the Virtual Investor Conference Small and Microcap Showcase

GlobeNewswire January 27, 2021

BioSig to Present at the 26th Annual International AF Symposium

GlobeNewswire January 15, 2021

BioSig PURE EP System Featured in the Editorial of EP Lab Digest

GlobeNewswire January 14, 2021

BioSig Deploys Vuzix M400 Smart Glasses to Offer Remote Servicing Capabilities in Compliance with COVID-19 Travel Restrictions

GlobeNewswire January 13, 2021

BioSig Conducts First Patient Cases with PURE EP(tm) System at Memorial Hospital of South Bend, Indiana

GlobeNewswire January 12, 2021

BioSig CEO Kenneth L. Londoner to Present at the Sidoti Winter 2021 Investor Conference

GlobeNewswire January 6, 2021

BioSig's Division NeuroClear Technologies Signs a Research Agreement with the University of Minnesota

GlobeNewswire December 18, 2020

BioSig Achieves First Commercial Sale of Three PURE EP Systems

GlobeNewswire December 11, 2020

BioSig CEO Kenneth L. Londoner to Present at the 13th Annual LD Micro Main Event Conference

GlobeNewswire December 10, 2020

BioSig to Highlight PURE EP(TM) System at the Benzinga Global Small Cap Conference

GlobeNewswire December 3, 2020

BioSig's PURE EP System to Support Live Patient Cases during EPLive 2020

GlobeNewswire November 30, 2020

BioSig to Host Business Update Conference Call on November 18, 2020

GlobeNewswire November 12, 2020

BioSig Announces Completion of PURE EP(TM) System Installation at New Medical Center

GlobeNewswire October 29, 2020

BioSig Issues October 2020 Shareholder Update Letter

GlobeNewswire October 28, 2020

ViralClear halts its Phase 2 Hospitalized COVID-19 Trial

GlobeNewswire October 26, 2020

SORRENTO THERAPEUTICS AND VIRALCLEAR ENTER INTO AGREEMENT TO EXPLORE THE COMBINATION OF ANTIBODY AND ANTIVIRAL ASSETS AGAINST COVID-19

GlobeNewswire September 30, 2020

ViralClear Expands Ongoing Phase 2 Trial Size for its Oral Anti-Viral for the Treatment of COVID-19, Expands Trial Locations and Appoints Contract Manufacturing Organization to Manufacture Phase 3 Supplies of Merimepodib Oral Solution

GlobeNewswire September 22, 2020

Reminder: ViralClear to Host Conference Call and Webcast on September 22, 2020 to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19

GlobeNewswire September 21, 2020